Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, it offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was fou
| 24.8 | |
| 25.96 | |
| - | |
| 26.09 | |
| 24.7 | |
| 14.4792-28.79 | |
| 9 884 M | |
| 31.3924 | |
| 399 M | |
| 1 184 M | |
| 0.21 | |
| 0.006 | |
| 0.748 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PREMIA Holdings (HK) Ltd. TOKYO and XIAMEN, China, March 27, 2023 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PRE...
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technol...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
